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Retroviral envelope proteins are heavily glycosylated. In some cases, glycosylation has been shown to be important for
folding, protein stability, immune evasion, or receptor usage. The receptor-binding subunit (SU or gp85) of the envelope
protein (EnvA) of the avian sarcoma/leukosis virus, subtype A (ASLV-A), contains 11 potential N-linked glycosylation sites
(NXS/T). To address the importance of N-linked glycosylation for the function of EnvA, we prepared a series of EnvA proteins
lacking one or more of these carbohydrate addition sites. Using site-directed mutagenesis, we mutated the S or T in each
NXS/T glycosylation sequon to A. We also prepared EnvAs bearing selected double and triple mutations. We examined each
mutant EnvA for its ability to be expressed at the cell surface, proteolytically processed into gp85 and gp37, incorporated into
MLV pseudotyped virions, and to support infection of cells expressing the ASLV-A receptor, Tva. Eight single mutations were
well tolerated, and, in general, EnvA was able to tolerate double mutations of these glycosylation sites. Triple mutations were
more variable in their effects. Of the three glycosylation sites important for EnvA function, two are important for folding (EnvA
production and processing were severely impaired). For the third, although EnvA processing was impaired, significant
amounts of processed EnvA were expressed at the cell surface and incorporated into virions. Nonetheless, this mutant EnvA,
EnvANg10, was unable to support infection. Further examination of EnvANg10 revealed that it was unable to bind Tva and
was severely impaired for binding to a monoclonal antibody which inhibits receptor binding. This work has therefore identified
a single N-linked glycosylation site in the SU domain of EnvA that is critical for binding between EnvA and its receptor, Tva.
© 2002 Elsevier Science (USA)
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Avian sarcoma/leukosis virus (ASLV), an alpharetrovi-
rus, is a major pathogen in poultry, causing sarcomas
and leukemias. As do other enveloped viruses, ASLV
enters target cells by a membrane fusion event. Fusion is
mediated by the single-surface glycoprotein, Env. Env is
initially synthesized as a single polypeptide chain which
forms trimers in the ER and is subsequently cleaved in
the Golgi into two subunits, SU (gp85), responsible for
receptor binding, and TM (gp37), the fusion-mediating
subunit (Einfeld and Hunter, 1988). The cleavage event,
which places Env in a metastable state, appears to be
needed for membrane fusion (Gilbert et al., 1995). By
analogy to other fusion proteins harboring two heptad
repeat coiled coil domains, the ASLV TM domain ap-
pears to follow a common fusion mechanism in which
the final fusion active form is thought to involve a six
helix bundle. The role of SU in the fusion process is less
well understood. Avian retroviral fusion has been studied
in the most detail for ASLV, subtype A (ASLV-A). Binding
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2 Current address: Medical College of Virginia; Virginia Common-All rof a single receptor, Tva, to the single viral glycoprotein,
EnvA, induces fusion-relevant conformational changes in
EnvA that activate it for fusion (Damico et al., 1998;
Gilbert et al., 1995; Hernandez et al., 1997). In contrast,
many receptor-mediated virus-cell fusion systems re-
quire multiple receptors and/or multiple viral glycopro-
teins. Thus, the ASLV system offers a tractable model for
studying the role of SU in receptor-mediated virus-cell
fusion.
N-linked glycosylation is important for glycoprotein
function. Retroviral glycoproteins are heavily glycosy-
lated, particularly in their SU domains. A primary function
of N-linked glycosylation is to ensure proper folding of
the glycoprotein (Ellgaard et al., 1999; Helenius and Aebi,
2001). N-linked glycosylation is also important for glyco-
protein stability (Fenouillet et al., 1990; Imperiali and
O’Connor, 1999). N-linked glycosylation has been ex-
ploited by many viral glycoproteins for immune evasion
(Bolmstedt et al., 1996; Kinsey et al., 1996; Reed et al.,
1997; Reitter et al., 1998; Schonning et al., 1996; Sjolander
et al., 1996; Willey et al., 1996). In addition, it can alter
protein–protein interactions, either directly or by altering
protein structure (see, for example, Rudd et al., 1999).
The ASLV-A glycoprotein, EnvA, contains 11 potential
glycosylation sites within the receptor-binding domain.infectivity.
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each of these sites singly and in combination and exam-
ined the ability of the resulting EnvAs to be expressed,
processed, incorporated into virions and to promote in-
fection of target cells expressing the ASLV-A receptor,
Tva. We also examined the ability of each mutant EnvA to
bind Tva and a monoclonal antibody which inhibits re-
ceptor binding. We found two sites which are important
for protein folding and one site which is essential for
receptor binding.
RESULTS
Predicted N-linked glycosylation sites in the SU
domains of ASLV Envs
As shown in Fig. 1A, there are 11 predicted N-linked
glycosylation sites in the receptor-binding subunit (SU) of
our EnvA isolate. These sites are numbered 1 through 11
in Fig. 1A. The majority of these sites are near, but not
within, variable regions of the protein thought to be
involved in receptor binding. A comparison of ASLV Env
SU sequences showed that there is a high degree of
conservation of glycosylation sites. Of the 11 sites in SU,
all but sites 1 and 5 are conserved among all ASLV Env
sequences examined (Fig. 1B). Furthermore, site 5 is
missing only in subtype D and is likely compensated for
by the adjacent 5 site not present in EnvA. For those SUs
harboring glycosylation sites 5 and 5, it is unlikely that
both are utilized simultaneously due to steric interfer-
ence among the glycosylation enzymes (Wu et al., 1995).
Additional glycosylation sites 5 and 10 are present in
most SU sequences but missing in EnvA, RAV 0-A 1, and
subtype C SUs. Thus, 10 of 14 possible sites are con-
served among all ASLV Env sequences of subtypes A–E
examined to date.
Generation of glycosylation deletion mutant EnvAs
The recognition sequon for N-linked glycosylation is
NXS/T, where X can be any residue except proline (Kas-
turi et al., 1997; Shakin-Eshleman et al., 1996). It has been
observed that deletion of glycosylation by substitution at
N is more often deleterious to protein structure than
substitution of S/T with A (Lee et al., 1992; Ohgimoto et
al., 1998). We therefore mutated the S or T in each of the
11 potential N-linked glycosylation sequons within the
SU subunit of EnvA to A. The mutant EnvAs are desig-
nated EnvAN-g followed by the number(s) of the site(s)
deleted.
Functional analysis of single glycosylation deletion
mutant EnvAs
We first examined the expression and processing of
each mutant EnvA after transient transfection of 293T
cells (Delos et al., 2000). As seen in Fig. 2A, most single
glycosylation site mutations were well tolerated. The
mutant EnvAs were expressed as well as wild-type EnvA
and processed into mature forms. However deletion of
either glycosylation site 2 or 6 (EnvAN-g2 and EnvAN-
g6, respectively) resulted in protein that was not pro-
cessed (no gp37 band observed in Fig. 2A, lanes “2” and
“6”). In addition, EnvA was poorly processed when gly-
cosylation site 10 was mutated (EnvAN-g10) (Fig. 2A,
lane “10”).
We next examined the ability of each mutant EnvA to
be incorporated into MLV pseudotyped virions. For those
mutant EnvAs which were processed normally, the pro-
cessed form of EnvA (see Fig. 3A) was incorporated into
virions. For EnvAN-g10, although processing was sig-
nificantly impaired, a reasonable amount of the pro-
FIG. 1. Diagram of the ASLV SU domain and comparison among subtypes A–E. (A) Map of the SU (gp85) domain of ASLV-A. The 11 potential N-linked
glycosylation sites are numbered consecutively and the amino acid position of the modified N is numbered below the line (numbering from the mature
SU N-terminus). The italic numbers in parentheses correspond to the numbers of these residues in the aligned sequence (Fig. 1B). The diagonally
hatched boxes denote “hr-1” and “hr-2,” variable regions known to be important for receptor choice; the vertically hatched boxes are additional variable
regions (Bova et al., 1986, 1988). Cysteines are designated “C.” (B) Alignment of SU sequences of ASLV subtypes A–E and comparison of their potential
glycosylation sites. SU sequences from ASLV genome data available from GenBank (RAV0-A1, AF257657; Schmidt-Ruppin A, S83510; type C,
NC001408; Prague C, V01197; Schmidt-Ruppin B, AF052428; Schmidt-Ruppin D, D10652; and RAV 0-E, M12172) were obtained and compared with the
sequence of our laboratory isolate using the ClustalW feature within the MacVector program. Sequences begin with the residue of the mature SU
after removal of the signal sequence and are numbered from this residue. Potential N-linked glycosylation sites are denoted with dashed-line boxes.
The potential sites present in our Env isolate are numbered 1 to 11. Those sites conserved among all SU sequences are circled. Additional sites in
other sequences not present in EnvA SU (gp85) are denoted with a prime or a double prime following the number of the immediately preceding site
in gp85. Although the box for site 2 spans four residues to accommodate differences in sequence alignment, the glycosylation sequon is the NCT/S
present in all sequences. Identical residues are against a dark gray background, conservative changes against light gray, and nonconserved
sequences, insertions, and deletions (represented by dashed lines) are against white.
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cessed form of EnvAN-g10 was incorporated into viri-
ons. This phenomenon has been seen previously (Delos
et al., 2000) and is likely due to preferential display of
processed EnvA at the cell surface, the site of virion
assembly. For the unprocessed mutant EnvAs, EnvAN-g2
and EnvAN-g6, no gp37 was incorporated into virions.
FIG. 2. Expression and processing of glycosylation deletion mutant EnvAs. 293T cells were transfected with 10 g pCB6-EnvA, induced with 10 mM
sodium butyrate 30 h post transfection, and harvested 48 h post transfection. Cells were lysed in lysis buffer [1% NP-40, 20 mM HEPES, pH 7.3, 130
mM NaCl], resolved by SDS–PAGE, transferred to nitrocellulose, and probed with an anti-Ngp37 antibody which recognizes both the TM subunit, gp37,
and the uncleaved precursor protein, pr95. The numbers above each lane indicate the glycosylation site(s) which has been mutated in the respective
EnvA. WTA, wild-type EnvA; Acl, a cleavage defective mutant EnvA (Gilbert et al., 1995).
FIG. 3. Incorporation of glycosylation deletion mutant EnvAs into MLV pseudotyped virions. ALSV-MLV pseudotyped virus was prepared by the
three-plasmid transfection method (Landau and Littman, 1992). 293T cells were transfected with 10 g each pHIT 60 (MLV gag-pol), pHIT111 (lacZ),
and pCB6-EnvA, induced with 10 mM sodium butyrate 30 h posttransfection, and harvested 48 h posttransfection. Virions were concentrated from cell
supernatants by pelleting through 20% sucrose, resuspended in sample buffer, resolved by SDS–PAGE, transferred to nitrocellulose, and probed with
the anti-Ngp37 antibody. An immunoblotting band, at approximately 70 kDa, is denoted with a filled arrowhead. Numbering is as for Fig. 2.
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In some cases (EnvAN-g2, EnvAN-g3, EnvAN-g4,
and EnvAN-g10), unprocessed material was incorpo-
rated into virions (Fig. 3A, the pr95 band), a characteristic
we also observe for the cleavage defective mutant, Acl.
In these instances, unprocessed EnvA is found at the cell
surface.
We next examined the ability of each mutant EnvA, in
the context of an MLV pseudotyped virion, to infect target
cells expressing the receptor for EnvA, Tva. Figure 4
shows the results of this analysis. For mutant EnvAs that
were well processed and readily incorporated into viri-
ons, approximate wild-type titers were observed. Con-
sistent with their lack of incorporation into virions (Fig. 3),
mutants EnvAN-g2 and EnvAN-g6 did not support
infection. Infectivity for EnvAN-g10 was reduced by
more than 1000-fold. The results of these studies are
summarized in Table 1.
Binding of receptor and a receptor-blocking mAb
To further define the defect in mutant EnvAN-g10, we
examined the ability of mutant EnvAs to associate with
their receptor, Tva, using a co-immunoprecipitation as-
say. For this assay, we employed a soluble fragment of
the receptor, s47, which has been shown to associate
with a soluble form of EnvA and induce conformational
changes that initiate fusion (Damico et al., 1998; Hernan-
dez et al., 1997). All single-mutant EnvAs except EnvAN-
g10 were able to bind s47 (Fig. 5). For EnvAN-g10, little
or no co-immunoprecipitation of s47 was observed, even
after prolonged exposures (data not shown).
An mAb against the SU subunit of EnvA has recently
been prepared which prevents s47 binding to EnvA (C.
Ochsenbauer-Jambor, S. E. Delos, J. M. White, and E.
Hunter, in press). We analyzed our mutant EnvAs for
reactivity with this mAb. We observed a significant defect
FIG. 4. Infectivity of glycosylation deletion mutant EnvAs. Aliquots from culture supernatants containing MLV pseudotyped virus, prepared as for
Fig. 3, were serially diluted and titered on PG950 cells (NIH3T3 cells stably expressing the ASLV-A receptor, Tva). Forty-eight hours postinfection, cells
were fixed, stained for -galactosidase activity, and blue cells counted. Numbering is as for Fig. 2.
TABLE 1
Summary of Results for EnvA Glycosylation Deletion Mutants
EnvA Processing
Virion
incorporation
of gp37
Infectivity
(% WTA)
Receptor
binding
Antibody
binding
WTA   100  
1   86  
2   0.0004 N.D. N.D.
3   63  
4   95  
5   582  
6   0.00013 N.D. N.D.
7   14  
8   37  
9   126  
10 /  0.03  /
11   246  
7, 9   130  
8, 9   66  
1, 11   84  
4, 11   167  
7, 8, 9  / 0.02  
5, 7, 9 /  0.11  
5, 8, 9 /  0.006  
7, 9, 11   246  
Note. The results from the immunoblots from respective experiments
were qualitatively evaluated for this table: , greater than or near
wild-type activity; , , and /, decreasing levels of activity; , no
activity observed. N.D., not done.
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in mAb binding to EnvAN-g10, but not to any of the
other mutant EnvAs (Fig. 6). These results have been
confirmed by a FACS-based binding assay (C. Ochsen-
bauer-Jambor, S. E. Delos, J. M. White, and E. Hunter, in
press; S. E. Delos, data not shown).
Functional analysis of multiple glycosylation deletion
mutant EnvAs
We also prepared selected double and triple glycosyl-
ation deletion mutant EnvAs. In choosing which mutant
FIG. 5. Receptor-binding: activity of glycosylation deletion mutant EnvAs. Cell lysates expressing mutant EnvAs were prepared as for Fig. 2 and
immunoprecipitated using an antibody against the cytoplasmic tail of EnvA. The beads with bound EnvA were then incubated with a biotinylated
fragment of the ASLV-A receptor, s47, for 30 min in the cold. The beads were then washed extensively and boiled in sample buffer, and the released
proteins resolved by SDS–PAGE, transferred to nitrocellulose, and probed with HRP-conjugated streptavidin to detect the biotinylated s47.  or 
denotes whether or not s47 has been added to the given immunoprecipitate. Numbering is as for Fig. 2.
FIG. 6. Binding of a function blocking antibody to the glycosylation deletion mutant EnvAs. Glycosylation deletion mutant EnvAs were expressed
and immunoprecipitated as described in the legend to Fig. 5. The beads with bound EnvA were then incubated with a monoclonal antibody against
the SU domain of EnvA, which blocks receptor binding (C. Ochsenbauer-Jambor, S. E. Delos, J. M. White, and E. Hunter, unpublished observations),
for 30 min in the cold. The beads were then washed and boiled in sample buffer, and the bound proteins resolved by SDS–PAGE and transferred to
nitrocellulose and probed with HRP-conjugated anti-mouse antibody. Numbering is as for Fig. 2.
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EnvAs to make, we asked whether we could delete, in
combination, those glycosylation sites which supported
near wild-type EnvA function when deleted singly. For the
triple glycosylation deletion mutations, particular interest
was placed on those glycosylation sites close to the
defined host-range determining sequences, sites 5, 7, 8,
and 9 (Fig. 1). As seen in Figs. 2B, 3B, 4, 5B, and 6B, and
summarized in Table 1, each of the double glycosylation
deletion mutants were well tolerated for all EnvA func-
tions examined. The results were more variable for triple
glycosylation deletion mutants. For EnvAN-g7,8,9 and
EnvAN-g7,9,11, processing appeared normal (Fig. 2B),
but only EnvAN-g7,9,11 was incorporated, as processed
EnvA, into virions (Fig. 3B). Therefore, as expected,
EnvAN-g7,8,9, EnvAN-g5,7,9, and EnvAN-g5,8,9 were
severely impaired in their ability to support infection, but
EnvAN-g7,9,11 exhibited wild-type levels of infectivity.
Each of the double and triple glycosylation deletion
mutant EnvAs were able to bind s47 (Fig. 5B) and the
receptor inhibiting mAb (Fig. 6B and data not shown).
However, EnvAN-g5,7,9 and EnvAN-g5,8,9 appeared
to exhibit decreased affinity for s47 (Fig. 5B). These
results identify one combination of triple N-linked glyco-
sylation deletions (EnvAN-g7,9,11), which is well toler-
ated by EnvA, and others (EnvAN-g5,79 and EnvAN-
g5,7,8), which are not.
DISCUSSION
To determine the role of N-linked glycosylation in EnvA
SU function, we mutated each of the potential N-linked
glycosylation sites in the SU domain individually and in
selected combinations and examined the ability of the
resulting EnvAs to be expressed, processed, and incor-
porated into virions, and to support infection of target
cells expressing the ASLV-A receptor, Tva. The ability of
each mutant EnvA to bind Tva and a monoclonal anti-
body which inhibits receptor binding was also examined.
Most single mutations were well tolerated, exhibiting
near wild-type function in all of the assays employed. All
double mutants exhibited near wild-type activity, whereas
most triple deletion mutants were severely impaired. In
the course of this analysis, we identified two sites es-
sential for EnvA structure, and, most importantly, a single
glycosylation site essential for receptor binding and
ASLV-A entry into target cells.
Relationship with other ASLV Envs
The glycosylation pattern in the SU domains of the
various ASLV subtypes retains a high degree of conser-
vation (Fig. 1B). Of the 11 potential glycosylation sites
present in EnvA SU, all but two sites, 1 and 5, are
conserved among all ASLV Env sequences examined,
and one of these, 5, is likely compensated for by an
adjacent site, 5, not present in EnvA. Deletion of the
other site, 1, had no apparent effect on EnvA function.
Three additional glycosylation sites, 5, 5, and 10, are
present in some SU domains but not in EnvA. As EnvA is
fully functional, these are likely nonessential. In sum-
mary, 9 (circled site numbers in Fig. 1B) of 14 possible
N-linked glycosylation sites are conserved among all
ASLV Env sequences of subtypes A–E examined to date.
This conservation of sequence notwithstanding, all but 3
of the 11 sites within the EnvA SU were found to be
individually dispensable for the EnvA functions we ex-
amined.
An important potential role of N-linked glycosylation of
viral glycoproteins is immune evasion. Indeed, much of
the mutational variation seen among and within HIV
clades under severe immune pressure results in altered
glycosylation patterns (Kinsey et al., 1996; McNearney et
al., 1992; Meyers et al., 1996; Overbaugh and Rudensey,
1992; Simmonds et al., 1991; Willey et al., 1996). It has
been difficult to isolate antibodies against the ASLV Env
SU subunits. Perhaps the ASLV Env has evolved a struc-
ture which is impervious to immune pressure so that
further evolution to escape antibody-induced neutraliza-
tion is selected against.
Role of glycosylation in folding
A primary function of glycosylation is to aid in proper
folding of the glycoprotein (Helenius and Aebi, 2001). We
found two glycosylation sites, 2 and 6, whose deletion
resulted in severely misfolded protein which was not
processed (Fig. 2), was poorly expressed at the cell
surface (S. E. Delos, unpublished results), and was not
incorporated into virions (Fig. 3); hence the resulting
virions were noninfectious. The importance of glycosyl-
ation at site 6 for EnvA structure may be due to its central
location between hr-1 and hr-2, regions important for
receptor choice and affinity (Dorner et al., 1985; Holmen
et al., 2001; Rong et al., 1997). Thus, glycosylation at site
6 likely plays a critical role in directing correct folding of
the central region of the SU subunit. Why site 2 appears
to be equally important is less clear. However, it has
been reported that glycoproteins are most sensitive to
removal of glycosylation sites near their N-termini, as
these sites first engage the ER protein folding machinery
to initiate the “correct” folding process (Doms et al., 1985;
Hebert et al., 1997; Helenius and Aebi, 2001). Site 2 is the
most N-terminal glycosylation site conserved among all
ASLV Envs (Fig. 1B). Our data do not directly distinguish
utilization of individual glycosylation sites, but since
EnvAN-g1 exhibits wild-type function, site 2 may be the
first glycosylation site used. Our data suggest that either
the sequences harboring sites 2 and 6, the sugar chains,
or both are important for the structure of EnvA. An alter-
native possibility is that substitution of A for the third
position S or T in the glycosylation sequon alters critical
structure by, for example, eliminating a critical hydrogen
bond.
Another reason sites 2 and 6 are important for folding
may be that the N to be modified is immediately followed
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by a cysteine. Thus, glycosylation at these sites may be
required for presentation of the adjacent cysteine for
proper disulfide bond formation. In contrast to sites 2 and
6, site 9, which is also adjacent to a cysteine, appears to
be unnecessary for proper folding. In this case, however,
the presence of two additional glycosylation sites (7 and
8) within the same cysteine-bound sequence may com-
pensate for the mutation at site 9 in controlling proper
orientation of its adjacent cysteine. Glycosylation of at
least one of these sites appears to be necessary for Env
structure (processed EnvAN-g7,8,9 was not incorpo-
rated into virions and these virions were unable to sup-
port infection of target cells), but apparently any two of
the three sites can be eliminated (EnvAN-g7,9 and
EnvAN-g8,9 exhibited near wild-type function). It has
been reported that when multiple glycosylation sites are
present in close proximity, they are not all used simulta-
neously and that mutation at one site can be compen-
sated for by utilization of another (Wu et al., 1995).
The effect of triple glycosylation deletions on EnvA
structure depended upon the combination of sites mu-
tated. As stated above, mutation of the 7,8,9 triplet
(EnvAN-g7,8,9) was not tolerated. Similarly, combining
mutation of site 5 with mutations of either 7 and 9
(EnvAN-g5,7,8) or 8 and 9 (EnvAN-g5,8,9) resulted in
severely defective EnvA. In contrast, combining muta-
tions at sites 7 and 9 with a mutation at site 11 (EnvAN-
g7,9,11) had no significant effect upon EnvA function.
Thus, it is not deletion of three glycosylation sites per se
that results in defective EnvA. Rather, in addition to the
requirement for at least one glycosylation site of the 7,8,9
trio, there must be some important cross-talk between
the sugar backbones of and/or the sequences surround-
ing sites 5 and the 7,8,9 segment for proper EnvA struc-
ture. Apparently, site 11 is not part of this cross-talk
network. Since s47 binding is decreased for both
EnvAN-g5,7,9 and EnvAN-g5,8,9 (Fig. 5), combinations
of mutations in sequences flanking the hr-1 and hr-2
regions apparently affect structure at the receptor-bind-
ing site as well as more global EnvA structure.
Processing of EnvA into its SU and TM subunits is
critical for EnvA function. N-linked glycosylation deletion
mutants, which were defective in EnvA function, were not
properly processed, and, in general, improperly pro-
cessed EnvA was poorly incorporated into virions. Sim-
ilar results have been observed for EnvAs harboring
mutations in the fusion peptide sequence within TM
(Delos et al., 2000). The exception to this observation is
EnvAN-g7,8,9, which appears, on the basis of the strong
gp37 band, to be processed (Fig. 2), yet little, if any,
processed EnvA is incorporated into virions (Fig. 3). This
may therefore represent the first case of a mutant EnvA
which is processed but not incorporated into virions.
This result suggests there may be additional, as yet
unknown, requirements for Env incorporation into virions.
Deletion of glycosylation sites often results in less
stable protein (Luo et al., 1993; Reitter and Desrosiers,
1998; Wu et al., 1995). It is interesting to note that for
many of the glycosylation deletion mutant EnvAs, a band
at approximately 70 kDa is observed in blots of virion
preparations. This band, not present for WTA (Fig. 3), is
reminiscent of the TM70 band observed on immunoblots
of EnvA isolated from virions after receptor-induced in-
activation (P. Bates, unpublished results; Mothes et al.,
2000). Perhaps EnvAs lacking glycosylation at these
sites have decreased stability in their native, metastable
states and are (partially) inactivated during either virion
incorporation or isolation. Nevertheless, for those EnvAs
which retained some gp37 in isolated virions, the ob-
served infectivity was near wild-type (Fig. 4), suggesting
that the presence of only a small amount of active EnvA
is sufficient to mediate infection. A similar result was
obtained when the cleavage-negative, infection-defec-
tive mutant EnvA, Acl, was coexpressed with EnvA in
MLV pseudotype experiments (S. E. Delos, unpublished
results).
A specific role for glycosylation site 10
The most striking result from our study is the identifi-
cation of a single glycosylation site, 10, whose deletion
abolished receptor binding. On a linear map, glycosyla-
tion site 10 is removed from the host-range determining
sequences in contrast to glycosylation sites 5, 7, 8, and 9,
each of whose individual mutation was well tolerated
(Fig. 1). A similar loss or gain of receptor binding has
been observed for HIV upon deletion or addition of spe-
cific single glycosylation sites (Dumonceaux et al., 2001;
Kolchinsky et al., 2001; Losman et al., 2001; Ly and
Stamatatos, 2000; Nakayama et al., 1998; Ogert et al.,
2001; Pollakis et al., 2001). In particular, loss of a glyco-
sylation site at the base of the V1/V2 loop rendered the
ADA variant HIV virus CD4 independent (Kolchinsky et
al., 2001). This was attributed to alteration of the V1/V2
loop orientation in the absence of the glycan, which
rendered the CCR5 binding region accessible without
prior CD4 binding. Perhaps a similar alteration of loop
orientation occurs in EnvAN-g10, in this case abolish-
ing the receptor-binding site. The simplicity of this mu-
tation may provide the opportunity to understand the
structural requirements for receptor binding. As dis-
cussed above for the sites 2 and 6 deletion mutants, it is
possible that the A substituted for S rather than the
glycan itself is important for EnvA structure. It is impor-
tant to note that while our data identify site 10 as impor-
tant for structure at the receptor-binding site, we have no
evidence of a direct interaction between s47 and either
the glycan or the S within the glycosylation sequon. For
HIV, comparable glycosylation mutations in different
strains do not always have equivalent effects on Env
structure and virus infectivity (Ogert et al., 2001). It will be
interesting to see if glycosylation site 10 is important for
other ASLV SUs to bind their respective receptors or is
uniquely important for EnvA.
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MATERIALS AND METHODS
Sequence comparison
Sequences for the SU domains of several Env proteins
of ASLV subtypes A–E were obtained from GenBank
(RAV0-A1, AF257657; Schmidt-Ruppin A, S83510; type C,
NC001408; Prague C, V01197; Schmidt-Ruppin B,
AF052428; Schmidt-Ruppin D, D10652; and RAV 0-E,
M12172). These sequences were aligned using ClustalW
option within MacVector (Oxford Molecular Group, Inc.).
Sequences are presented from the first residue after
cleavage of the ER translocation signal sequence and
are numbered starting with this residue.
Reagents for expression and detection of EnvA
MVA, an avian-tropic vaccinia virus encoding T7 poly-
merase, was a gift from Dr. Bernard Moss (National
Institutes of Health). 293T and PG950 cells have been
(Gilbert et al., 1995). PG950 cells express the ASLV-A
receptor, Tva. Cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) containing 10% supple-
mented calf serum (Hy-Clone, Ogden, UT) and 500 mg
Geneticin per liter, supplemented with 1 glucose, 1
pyruvate, and 1 penicillin/streptomycin (Gibco-BRL).
pCB6 plasmids encoding EnvA and the EnvA cleavage-
negative mutant, Acl, have been described (Gilbert et al.,
1995). The anti MLV-gag, anti-Ngp37, and anti-EnvA tail
antibodies have been described (Gilbert et al., 1994;
Hernandez and White, 1998). Protocols and plasmids for
the purification of s47, a functional recombinant fragment
of the ASLV-A receptor, were gifts from Dr. R. Peters and
Dr. D. Agard, University of California at San Francisco.
s47 was biotinylated as previously described (Delos et
al., 2000).
Mutagenesis
Mutations to convert the serine or threonine in each
N-X-S/T sequon within SU to alanine were introduced
into the pCB6/EnvA plasmid using the Quick-Change
mutagenesis kit (Stratagene) according to the manufac-
turers instructions. The resulting EnvA genes were se-
quenced (DNA Sequencing Core, Biomolecular Re-
search Facility, University of Virginia School of Medicine)
to verify the presence of desired mutation and the ab-
sence of spurious mutations.
Protein expression, pseudotype virus production, and
infectivity
EnvA expression, incorporation into MLV pseudotyped
virions, and the infectivity assay were performed as pre-
viously described (Delos-pro).
s47 and 8C5.4 binding to EnvA
To assay for s47 binding to EnvA, 100 l of lysate from
cells expressing a given EnvA was precleared with pre-
immune serum bound to protein A beads, immunopre-
cipitated with the anti-A tail antibody, washed twice with
lysis buffer, and then incubated for 30 min at 4°C with 1
l of biotinylated s47. After additional washing, samples
were boiled in SDS–PAGE sample buffer, resolved by
SDS–PAGE, transferred to nitrocellulose, and probed
with horseradish peroxidase conjugated streptavidin.
The assay for binding of the monoclonal antibody, 8C5.4,
to EnvA was similar except that 1 l of antibody was
substituted for the s47 and the immunoblot was probed
with horseradish peroxidase conjugated anti-mouse an-
tibody.
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